Skip to content

Retrospective cohort study of Sandan Tongluo granule in the treatment of ischemic stroke in convalescent period

Real world clinical research and development application of Roogan Tongluo Granule (renamed Sangdan Tongluo granule) in the treatment of ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2200005576
Enrollment
Unknown
Registered
2022-01-31
Start date
2022-02-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Non-exposure group:conventional western medicine treatment
Exposed group:Sandan Tongluo granules + conventional western medicine treatment

Sponsors

Affiliated Hospital of Hunan Academy of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Western diagnosis conforms to the diagnostic criteria of ischemic stroke;? TCM diagnosis belongs to apoplexy;? The duration of the disease is between 2 weeks and 6 months;? Good compliance, aged between 18 and 75 years old;(5) with limb dysfunction, and not accompanied by other diseases affecting neurological function and life ability evaluation;? Patients or their family members agree and sign informed consent.

Exclusion criteria

Exclusion criteria: ? The course of treatment is less than 1 month;? The medical records are not complete, and the return visit cannot be obtained.

Design outcomes

Primary

MeasureTime frame
Stroke syndrome diagnosis scale;Degree of neurological impairment;Efficacy end points (fatality rate, recurrence rate);Degree of disability;Cognitive level;Ability to perform daily living activities;

Secondary

MeasureTime frame
The basic information;

Countries

China

Contacts

Public ContactMao Guo
511467235@qq.com0731-88883760

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026